 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type 1 HRS-1, an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.1 The study, funded by Mallinckrodt, found that terlipressin was associated with an improvement in kidney function among HRS-1 patients as measured by a reduction in serum creatinine SCr. The results of the study were published in the peer-reviewed journal Alimentary Pharmacology and Therapeutics. 